Zanubrutinib or Ibrutinib in Relapsed or Refractory Chronic Lymphocytic Leukemia

Jennifer R. Brown; Barbara Eichhorst; Peter Hillmen; Wojciech Jurczak; Maciej Kaźmierczak; Nicole Lamanna; Susan O’Brien; Constantine S. Tam; Lugui Qiu; Keshu Zhou; Martin Šimkovič; Jiřı́ Mayer; Amanda Gillespie-Twardy; Alessandra Ferrajoli; Peter Ganly; Robert Weinkove; Sebastian Grosicki; Andrzej Mital; Tadeusz Robak; Anders Österborg; Habte Yimer; Tommi Salmi; Megan-Der-Yu Wang; Lina Fu; Jessica Li; Kenneth Wu; Aileen Cohen; Mazyar Shadman

doi:10.1056/nejmoa2211582

Ask about this paper

Answers are grounded in this paper and cite their sources.

Abstract

In patients with relapsed or refractory CLL or SLL, progression-free survival was significantly longer among patients who received zanubrutinib than among those who received ibrutinib, and zanubrutinib was associated with fewer cardiac adverse events. (Funded by BeiGene; ALPINE ClinicalTrials.gov number, NCT03734016.).

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Brown et al. (2022) studied this question.

synapsesocial.com/papers/69d9a6678988aeabbe685eb8 https://doi.org/10.1056/nejmoa2211582

View Full Paper

Ask AI

Bookmark

Share

Zanubrutinib or Ibrutinib in Relapsed or Refractory Chronic Lymphocytic Leukemia

Ask about this paper

Abstract

Discussion

Cite This Study

Zanubrutinib or Ibrutinib in Relapsed or Refractory Chronic Lymphocytic Leukemia

Ask about this paper

Abstract

Discussion

Cite This Study

Keep reading

Keep reading